Evidence map›Paper›PMID 37023111›Full record

SynthesisPloS one2023

NAT2 global landscape: Genetic diversity and acetylation statuses from a systematic review.

Jorge E Gutiérrez-Virgen, Maricela Piña-Pozas, Esther A Hernández-Tobías, Lucia Taja-Chayeb, Ma de Lourdes López-González, Marco A Meraz-Ríos, Rocío Gómez

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.Clinical pharmacology and therapeutics · 2026
    Review
  5. Article
  6. Pharmacogenomic heterogeneity ofAnnals of medicine · 2025
    Observational
  7. Article
  8. Clinical Medicine Insights. Oncology · 2025
    Article
  9. Variants in theJournal of clinical tuberculosis and other mycobacterial diseases · 2024
    Article
  10. Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Human N-acetyltransferase 2 (Frontiers in pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jorge E Gutiérrez-VirgenDepartamento de Toxicología, CINVESTAV-IPN, Mexico City, Mexico.ORCID 0000-0002-2842-3035
Maricela Piña-PozasInstituto Nacional de Salud Pública, Centro de Información para Decisiones en Salud Pública, Mexico City, Mexico.
Esther A Hernández-TobíasFacultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Lucia Taja-ChayebDivisión de Investigación Básica, Instituto Nacional de Cancerología, Mexico City, Mexico.ORCID 0000-0002-9592-8527
Ma de Lourdes López-GonzálezDepartamento de Toxicología, CINVESTAV-IPN, Mexico City, Mexico.
Marco A Meraz-RíosDepartamento de Biomedicina Molecular, CINVESTAV-IPN, Mexico City, Mexico.ORCID 0000-0001-6748-8117
Rocío GómezDepartamento de Toxicología, CINVESTAV-IPN, Mexico City, Mexico.ORCID 0000-0002-9653-7501
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXInstituto Nacional de Cancerología · MXInstituto Nacional de Salud Pública · MXUniversidad Autónoma de Nuevo León · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Arylamine N-acetyltransferase 2 has been related to drug side effects and cancer susceptibility; its protein structure and acetylation capacity results from the polymorphism's arrays on the NAT2 gene. Absorption, distribution, metabolism, and excretion, cornerstones of the pharmacological effects, have shown diversity patterns across populations, ethnic groups, and even interethnic variation. Although the 1000 Genomes Project database has portrayed the global diversity of the NAT2 polymorphisms, several populations and ethnicities remain underrepresented, limiting the comprehensive picture of its variation. The NAT2 clinical entails require a detailed landscape of its striking diversity. This systematic review spans the genetic and acetylation patterns from 164 articles from October 1992 to October 2020. Descriptive studies and controls from observational studies expanded the NAT2 diversity landscape. Our study included 243 different populations and 101 ethnic minorities, and, for the first time, we presented the global patterns in the Middle Eastern populations. Europeans, including its derived populations, and East Asians have been the most studied genetic backgrounds. Contrary to the popular perception, Africans, Latinos and Native Americans have been significantly represented in recent years. NAT2*4, *5B, and *6A were the most frequent haplotypes globally. Nonetheless, the distribution of *5B and *7B were less and more frequent in Asians, respectively. Regarding the acetylator status, East Asians and Native Americans harboured the highest frequencies of the fast phenotype, followed by South Europeans. Central Asia, the Middle East, and West European populations were the major carriers of the slow acetylator status. The detailed panorama presented herein, expands the knowledge about the diversity patterns to genetic and acetylation levels. These data could help clarify the controversial findings between acetylator states and the susceptibility to diseases and reinforce the utility of NAT2 in precision medicine.

Indexed as

Arylamine N-AcetyltransferaseAcetylationGenotypeHaplotypesPhenotypePolymorphism, GeneticArylamine N-Acetyltransferase

Identifiers

PMID37023111
PMCPMC10079069
OpenAlexW4362657523

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.